Bovine leukemia virus (BLV) is a retrovirus that is highly prevalent in US dairy herds: over 83% are BLV infected and the within-herd infection rate can be almost 50% on average. While BLV is known to cause lymphosarcomas, only 5% or fewer infected cattle will develop lymphoma; this low prevalence of cancer has historically not been a concern to dairy producers. However, more recent research has found that BLV + cows without lymphoma produce less milk and have shorter lifespans than uninfected herdmates. It has been hypothesized that BLV infection interferes with normal immune function in infected cattle, and this could lead to reduced dairy production. To assess how naturally infected BLV + cows responded to a primary and secondary immune challenge, 10 BLV + and 10 BLV − cows were injected subcutaneously with keyhole limpet hemocyanin (KLH) and dimethyldioctadecylammonium bromide. B-and T-cell responses were characterized over the following 28 days. A total of 56 days after primary KLH exposure, cows were re-injected with KLH and B-and T-cell responses were characterized again over the following 28 days. BLV + cows produced less KLHspecific IgM after primary immune stimulation; demonstrated fewer CD45R0 + B cells, altered proportions of CD5 + B cells, altered expression of CD5 on CD5 + B cells, and reduced MHCII surface expression on B cells ex vivo; exhibited reduced B-cell activation in vitro; and displayed an increase in BLV proviral load after KLH exposure. In addition, BLV + cows had a reduced CD45R0 + γδ + T-cell population in the periphery and demonstrated a greater prevalence of IL4-producing T cells in vitro. All together, our results demonstrate that both B-and T-cell immunities are disrupted in BLV + cows and that antigen-specific deficiencies can be detected in BLV + cows even after a primary immune exposure.
Bovine leukemia virus (BLV) is a retrovirus that is highly prevalent in US dairy herds: over 83% are BLV infected and the within-herd infection rate can be almost 50% on average. While BLV is known to cause lymphosarcomas, only 5% or fewer infected cattle will develop lymphoma; this low prevalence of cancer has historically not been a concern to dairy producers. However, more recent research has found that BLV + cows without lymphoma produce less milk and have shorter lifespans than uninfected herdmates. It has been hypothesized that BLV infection interferes with normal immune function in infected cattle, and this could lead to reduced dairy production. To assess how naturally infected BLV + cows responded to a primary and secondary immune challenge, 10 BLV + and 10 BLV − cows were injected subcutaneously with keyhole limpet hemocyanin (KLH) and dimethyldioctadecylammonium bromide. B-and T-cell responses were characterized over the following 28 days. A total of 56 days after primary KLH exposure, cows were re-injected with KLH and B-and T-cell responses were characterized again over the following 28 days. BLV + cows produced less KLHspecific IgM after primary immune stimulation; demonstrated fewer CD45R0 + B cells, altered proportions of CD5 + B cells, altered expression of CD5 on CD5 + B cells, and reduced MHCII surface expression on B cells ex vivo; exhibited reduced B-cell activation in vitro; and displayed an increase in BLV proviral load after KLH exposure. In addition, BLV + cows had a reduced CD45R0 + γδ + T-cell population in the periphery and demonstrated a greater prevalence of IL4-producing T cells in vitro. All together, our results demonstrate that both B-and T-cell immunities are disrupted in BLV + cows and that antigen-specific deficiencies can be detected in BLV + cows even after a primary immune exposure. inTrODUcTiOn Bovine leukemia virus (BLV) is a δ-retrovirus (1) that infects over 83% of dairy herds in the United States; as many as 40% of all US dairy cattle are infected (2) . BLV is the causative agent of enzootic bovine leukosis (EBL), where BLV + cattle develop malignant lymphoma or leukemia (3) . Although lymphoma is deadly and results in carcass condemnation at slaughter (2) , it is estimated that fewer than 10% of infected cattle will eventually develop EBL (3) . Unfortunately, recent research suggests that BLV infection has more negative impacts on herd health than previously appreciated.
Bovine leukemia virus infection reduces both milk production (2) and longevity (4) in infected dairy cows. While it is unclear how BLV interferes with milk production and lifespan, one hypothesis is that BLV causes immune dysregulation, which could put BLV + cattle at an increased risk for other infections. BLV most commonly infects B cells (5) and can cause persistent lymphocytosis (PL), a chronic, benign, polyclonal expansion of the B-cell compartment that occurs in 30% of infected cattle (3) .
In vitro experiments have demonstrated abnormalities in both innate and adaptive immune cells isolated from BLV + cattle (6) . In addition, a few studies have found positive correlations between BLV and other infectious diseases (7, 8) and a reduction in vaccine immunity in BLV + cattle (9) (10) (11) . However, when investigating immunity in naturally infected BLV + cattle, many studies were unable to control for how much antigen exposure occurred before or after BLV infection.
The current study was designed to address that specific problem. BLV + and BLV − cows were exposed to an immunostimulatory antigen, keyhole limpet hemocyanin (KLH), to mimic a primary immune response. At 56 days after primary exposure, cows were re-exposed to KLH to mimic a secondary memory immune exposure. To characterize both primary and secondary adaptive immune responses, B-and T-cell responses were tracked using ELISAs to measure antibody production against KLH, flow cytometry to measure the dynamics of freshly isolated B and T cell subsets, and cell culture to investigate B-and T-cell responses to KLH and mitogenic stimulation in vitro. Specifically, CD5 and CD45R0 expressions on ex vivo B cells and CD45R0 expression on ex vivo CD4 + , CD8
+ , and γδ + T cells were characterized. BLV and CD25 expressions were characterized in B cells, and IFNγ and IL4 productions were characterized in T cells after in vitro stimulation. Abnormalities in both B-and T-cell subsets were detected in BLV + cattle during both primary and secondary immune responses, providing further support that BLV infection causes immune dysregulation.
MaTerials anD MeThODs animals and Klh inoculation

BLV
− and 10 BLV + lactating Holstein dairy cows were enrolled in the current study ( Table 1) . BLV + cows (as determined by the producer's BLV milk ELISA results) were not confirmed to have PL but were selected for elevated total leukocyte counts (as determined using a Beckman Coulter counter) and an elevated proportion of circulating B cells [as determined by immunostaining for surface IgM (SIgM) on freshly isolated PBMCs] 1 week prior to the study's initiation. BLV + cows had a high proviral load (PVL) on d0 (12). BLV − cows were then age and lactation matched to the 10 selected BLV + cows. Both BLV − and BLV + cows were also re-screened for BLV infection using a commercial serum ELISA (NorthStar Cooperative) 1 week prior to the study start. BLV serum ELISAs and endpoint PCR (on DNA extracted from whole blood) to detect BLV provirus were also used on samples collected on the first and last days of the study to confirm BLV status. One BLV − cow seroconverted in between enrollment diagnostics and the start of the study; this cow and her matched BLV + cow were excluded from the final data analysis. Upon study initiation on day 0 (d0), all cows received the primary KLH inoculation consisting of 1.5 mL KLH cocktail injected subcutaneously into the left side of the neck. The KLH cocktail was composed of 200 µg KLH (Sigma) in 0.75 mL 1× phosphate-buffered saline (PBS) containing 5% bovine serum albumin and 0.75 mL 20 mg/mL adjuvant dimethyldioctadecylammonium bromide (DDA) (Sigma) in 1× PBS (13) . On d56, cows received the secondary KLH inoculation with 1.5 mL KLH cocktail subcutaneously injected into the right side of the neck. All protocols were reviewed and approved by the Michigan State University Institutional Animal Use and Care Committee (AUF# 04/15-061-00).
Whole Blood, Plasma, and PBMc isolation Whole blood was collected by coccygeal venipuncture on d0 before primary inoculation and on days 7, 14, 18, 21, 28, 54, and 56 after primary inoculation; after blood collection on d56, the secondary KLH inoculation was administered and blood was collected on days 60, 67, 70, 77, and 84 after primary inoculation (days 4, 11, 14, 21, and 28 after secondary inoculation). Blood for PVL quantification was collected in Vacutainer blood collection tubes containing the anticoagulant EDTA (Becton Dickinson); 1 mL aliquots of whole blood were stored at −80°C. Blood for antibody quantification and PBMC immunostaining was collected in Vacutainer blood collection tubes containing the anticoagulant ACD (Becton Dickinson). Plasma and PBMCs were isolated as previously described (10) . Briefly, aliquots of plasma with 0.1% sodium azide were stored at −80°C and PBMCs were isolated using Percoll density centrifugation. BlV PVl Quantification DNA was extracted from whole blood using the DNeasy Blood and Tissue kit (Qiagen) using a modified protocol. Briefly, 200 µL of whole blood, 40 µL of proteinase K, 218 µL of buffer AL and 218 µL of 100% ethanol were used instead of the recommended kit volumes. Extracted DNA was quantified using a Nanodrop-1000, and A260/280 ratios were used to assess sample purity. DNA was diluted to 30 ng/µL in elution buffer for PVL quantification. BLV PVL was determined using the Coordination of Common Motifs-qPCR to amplify the long terminal repeat (LTR) of the BLV provirus. To normalize genomic DNA input, the single-copy Bola-DRA gene was also amplified (14) . In brief, 30 ng of genomic DNA were assayed using TaqMan Gene Expression Master Mix (Applied Biosystems, CA, USA) on the 7500 FAST Real-time PCR System (Applied Biosystems, CA, USA). BLV copy number and BoLA-DRA copy number were calculated using 10-1 × 10 5 copies of the standard plasmid, which contained a copy of BLV-LTR and BoLA-DRA. Each value was calculated using the algorithm suggested by the manufacturer. PVL was the ratio of BLV copy number to BoLA-DRA copy number multiplied by 100,000 (15) . PVL was expressed as BLV copy number/100,000 cells.
anti-Klh antibody Quantification
Anti-KLH antibodies were quantified from plasma collected on days 0, 7, 14, 21, 28, 56, 60, 67, 70, 77, and 84 after primary inoculation. Flat-bottomed 96-well ELISA plates (Thermo Fisher Scientific) were incubated with 100 µL of 1 µg/mL KLH in 50 mM carbonate/bicarbonate buffer overnight at 4°C. Plates were washed 3× with wash buffer (0.05% Tween-20 in 1× PBS) and blocked with 2% heat-inactivated horse serum in wash buffer for 1 h at 37°C. Plates were then washed 5×, and 100 µL of plasma (diluted 1:50 in blocking buffer) was added to wells and incubated for 1 h at room temperature. Plates were washed 5× and then incubated for 1 h at room temperature with 100 µL antibovine IgM, IgG1, or IgG2 conjugated to horseradish peroxidase (Thermo Fisher Scientific) diluted 1:10,000 in blocking buffer as previously described (10) . Plates were washed 5× and incubated for 15 min at room temperature in the dark with 100 µL TMB substrate (Sigma). A total of 100 µL stop solution (2 M H2SO4) was added, and the optical density was measured at 450 nm using a SpectraMax M5 microplate reader. All samples were run in duplicate, and each plate included blank and naive (not exposed to KLH) controls.
immunostaining of Freshly isolated PBMcs
Immunostaining of freshly isolated PBMCs was performed as previously described (10) on days 0, 7, 14, 21, 28, 56, 60, 67, 70, and 77 after primary inoculation. Briefly, 5 × 10 5 PBMCs were fixed in 4% paraformaldehyde and then labeled via indirect immunofluorescence first with mouse anti-bovine primary antibodies and second with goat anti-mouse secondary antibodies. The freshly isolated B-cell population was characterized using the stain labeled "fresh B" in Table 2 , and the freshly isolated T-cell population was characterized using the stain labeled "fresh T" in Table 2 .
In Vitro stimulation of PBMcs
To investigate T-cell activation, 2 × 10 6 PBMCs were cultured at 38°C and 5% CO2 in 1 mL Roswell Park Memorial Institute (RPMI) complete media (RPMI plus 10% fetal bovine serum, 1% penicillin/ streptomycin, and 1% fungizone, pH 7.4) in 24-well culture plates (Corning). PBMCs were either cultured in medium alone (NIL) for 18 h, with 200 µg/mL KLH for 18 h, or with 20 µg/mL positive control concanavalin A (CONA) for the final 6 h. All samples were treated with 20 ng/mL brefeldin A at 12 h to prevent cytokine secretion. T-cell activation was measured on days 7, 14, 56, 67, and 77.
To investigate B-cell activation, 5 × 10 6 PBMCs were cultured at 38°C and 5% CO2 in 3 mL RPMI complete media in 12-well culture plates (Corning) with medium alone (NIL), 200 µg/mL KLH, or with positive control 20 ng/mL phorbol 12-myristate 13-acetate and 400 ng/mL ionomycin (P/I) for 18 h. B-cell activation was measured on days 18, 54, and 70.
immunostaining of cultured PBMcs
PBMCs were labeled with four-color stains to investigate IFNγ production by T cells ("IFNγ" in Table 2 ), IL4 production by T cells ("IL4" in Table 2 ), and BLV expression in B cells ("CD45R0" and "CD25" in Table 2 ). Immunostaining of cultured PBMCs was performed as previously described (10) . Briefly, indirect immunostaining for surface receptors on live PBMCs was done as described for freshly isolated PBMCs. PBMCs were then fixed and permeabilized using a fixation/permeabilization kit according to manufacturer's instructions (eBioscience), and PBMCs were labeled with a primary mouse anti-bovine or anti-BLV monoclonal antibody and subsequently labeled with a goat anti-mouse secondary antibody. Labeled PBMCs were stored at 4°C overnight until flow cytometry analysis.
immunostaining analysis
Data were acquired using an Accuri C6 flow cytometer equipped with CSampler (Becton Dickinson). Data were compensated using the Accuri C6 software (Becton Dickinson) and then exported for analysis using FCS Express 4 (De Novo Software). PBMCs were initially selected using forward and side scatter gating to exclude debris, and cells were identified gating on lineage-specific markers (CD4, CD8, γδ, or SIgM). Expression of IFNγ, IL4, CD45R0, MHCII, CD5, and CD25 were then subsequently characterized within specific cell types, and marker expression was expressed as either the mean relative percent or the mean fluorescence intensity (MFI). Unless noted, all referenced B cells are SIgM + MHCII + . CD5 labeling on fresh PBMCs exhibited three populations; the center population was denoted "CD5 
statistics
Statistical analysis was performed using SAS 9.4 (SAS Institute). Antibody and fresh PBMC data were analyzed using repeated measures ANOVA with BLV and time as fixed effects and post hoc Bonferroni correction for pairwise comparisons. Cultured PBMC data were analyzed using repeated measures ANOVA with BLV and stimulant as fixed effects and post hoc Bonferroni correction for pairwise comparisons. A Tukey test was used to analyze the difference in MHCII or CD25 MFIs between different B-cell subsets. Outliers were detected using Grubbs test; both outliers and their matched cow were eliminated from analysis. Significance was determined as p < 0.05.
resUlTs
BlV
+ cows exhibit reduced igM Production In Vivo
To characterize the strength of the humoral immune response in BLV + cows, the relative quantities of KLH-specific IgM, IgG1, and IgG2 were measured. As expected, both BLV + and BLV − cows produced KLH-specific IgM, IgG1, and IgG2 after primary and secondary KLH inoculations (p < 0.001 for all isotypes). Interestingly, BLV + cows had less IgM (p = 0.0045) after primary KLH inoculation at all time points, including d0. However, BLV + cows made IgM at levels equal to BLV − cows after the secondary KLH inoculation (p = 0.7742) ( Figure 1A) . In contrast to IgM production, BLV + and BLV − cows produced equivalent levels of IgG1 (p = 0.6715) ( Figure 1B) and IgG2 (p = 0.9437) ( Figure 1C ) after both primary and secondary KLH inoculations. These data support recent evidence that BLV infection interferes with IgM antibody production after both a primary immune challenge and a common vaccine booster injection (10 (Figure 2A) . When analyzing CD5 expression on B cells, two distinct positive populations were observed, which we denoted CD5 dim and CD5 bright ( Figure  S1 in Supplementary Material). Interestingly, B cells from BLV Although the surface expression of CD5 did not change over time, both CD5 dim+ and CD5 bright+ B-cell populations responded to KLH inoculation (p < 0.05); while the CD5 dim+ B-cell population steadily increased after inoculation, the CD5 bright+ B-cell population sharply declined. In addition, BLV + cows displayed a lower CD5 dim+ B-cell population (p = 0.0043) (Figure 2D ), but the CD5 bright+ B-cell population was equal between BLV + and BLV − cows (p = 0.9611) ( Figure 2E ). We were also interested in the effect of BLV infection on MHCII surface expression. Surprisingly, MHCII surface expression actually fluctuated in response to KLH exposure on all measured B-cell types (p < 0.05). BLV + cows presented lower MHCII surface expression on CD5 dim+ B cells (p = 0.0168) ( Figure 2G ) 
BlV PVl In Vivo increases after Klh inoculation
In order to assess how the BLV PVL changed over time after KLH+ DDA exposure, DNA was extracted from whole blood from BLV + cattle and qPCR was used to measure PVL. The average BLV PVL on d0 before inoculation was almost 96,000 copies/10 5 cells; after both primary and secondary KLH inoculations, the PVL sequentially increased over time (p < 0.0001) (Figure 5) . BLV + cows exhibited the largest increase in PVL on the final day of collection (28 days post-exposure for primary and 21 days post-exposure for secondary); in both cases, the PVL increased by over 18,000 copies/10 5 cells.
BlV
+ cows have reduced Proportions of circulating T-cell Populations In Vivo
Although BLV most commonly infects B cells, previous research has suggested that T-cell immunity is also compromised in BLV + cows (6) . To investigate the circulating effector and memory T-cell population in BLV + cows after KLH inoculation, we labeled freshly isolated PBMCs to measure CD45R0 expression on CD4 + , CD8
+ , and γδ + T cells. BLV + cows consistently exhibited lower − B cells, ⬪⬪ p < 0.05 compared to nil. Different letters denote significant differences. n = 8-9/group. Data represent the mean ± SEM.
FigUre 5 | Bovine leukemia virus (BLV) proviral load (PVL) in whole blood in BLV + cows. DNA was extracted from whole blood collected from BLV + cows after keyhole limpet hemocyanin (KLH) inoculation and the BLV PVL was measured. The change in PVL after either primary (d0) or secondary (d56) KLH+ DDA injection was determined. ⬪⬪ p < 0.05 compared to d0 (for primary) or to d56 (for secondary), ⬪ p < 0.1 compared to d0 or d56. n = 10. Data represent the mean ± SEM. 
T cells from BlV + cows Produce More il4 after stimulation In Vitro
In addition to investigate the circulating effector/memory T-cell compartment, we examined whether T cells from BLV + cows generated IFNγ or IL4 in response to stimulation in vitro. While in vitro T-cell activation was measured on d7, 14, 56, 67, and 77, there was no difference between time points; thus, the IFNγ data presented in Figure 7 is from d56. Overall, KLH stimulation failed to increase the proportion of IFNγ + cells in any T-cell subset and actually decreased the proportion of IFNγ + CD8 + T cells from both BLV + and BLV − cows. There was no overall difference between BLV + and BLV − cows in the proportion of IFNγ Figure 7D ). We also studied IL4 production by T-cell subsets in BLV + cows. Similar to the in vitro IFNγ results, in vitro IL4 production was not different between time points; thus, the IL4 data presented in Figure 8 are from d77. Surprisingly, in vitro IL4 production was not similar to what was observed with in vitro IFNγ production. BLV status had a significant or trending significant effect on the proportion of IL4-producing cells within CD4 + (p = 0.0009), CD8 + (p = 0.0006), and γδ + T-cell (p = 0.0879) populations. In relative proportions of CD4 + , CD8 + , and γδ + T cells (p < 0.05) (Figure 6D ), although these did not change over time. However, both CD4 + CD45R0 + ( Figure 6A ) and CD8 
CD450
+ T-cell population (p < 0.0001) ( Figure 6C ). These data indicate that while BLV infection does not appear to affect the classical effector/memory T-cell all three T-cell populations, BLV + cows consistently exhibited a higher proportion of IL4-producing T cells (Figures 8A-C) . However, reactive CD8 + T cells from BLV + cows actually exhibited lower IL4 expression in comparison to reactive CD8 + T cells from BLV − cows (p < 0.0001) ( Figure 8D ). The IL4 MFI from CD4 + and γδ + T cells was not different between BLV + and BLV − cows (data not shown). Taken together, these results imply that T cells from BLV + cows are capable of producing both IFNγ and IL4 after in vitro cell culture; however, the balance in BLV + cows may favor a greater proportion of IL4-producing T cells.
DiscUssiOn
In this study, we investigated how BLV + dairy cows respond to both a primary immune stimulation and a secondary immune stimulation. After exposing BLV + and BLV − cows to a noninfectious antigen (KLH), both B-and T-cell responses were tracked over a 3-month period to measure both the primary and secondary immune responses. Alterations were observed in both B-and T-cell immunities in BLV + cows relative to uninfected herdmates: BLV + cows produced lower titers of KLH-specific IgM after primary immune stimulation; exhibited fewer CD45R0 + cows more vulnerable to other infections of economic importance. This risk is readily apparent at first exposure to a novel antigen as well as after repeated exposure to a common vaccine (10) .
Similar to results seen in previous studies (10, 11) , BLV + cows demonstrated less antigen-specific IgM after primary stimulation. Although BLV + cows produced equivalent levels of IgM after secondary stimulation, this appears to be the result of IgM levels declining in BLV − cows between primary and secondary stimulations. In contrast, no differences were observed in either IgG1 production or IgG2 production against KLH. While other studies have found altered IgG levels in BLV + cattle (9, 11), it is possible that any impairment of IgG production is only detectable after repeated antigen exposure. While IgG antibodies have higher affinity for antigens, IgM is particularly important during a primary immune response as the first secreted isotype and is especially important for activating complement, which provides critical protection against bacterial infections.
It was interesting to note that the overall circulating B-cell population in BLV + cows alone increased after both primary and secondary KLH stimulations. 30% of BLV + cattle develop PL, which is characterized by a chronic, polyclonal expansion of B cells in peripheral blood (3) . While the mechanisms by which BLV causes PL are not well understood, B-cell population dynamics are clearly dysregulated during polyclonal expansion Abnormal Immunity in BLV + Cows
Frontiers in Veterinary Science | www.frontiersin.org July 2017 | Volume 4 | Article 112 (6) . Because the prevalence of circulating B cells in BLV + cows did not remain elevated between primary and secondary stimulations, it suggests that the prevalence of circulating B cells in the periphery was the result of KLH+ DDA exposure. It was especially intriguing that the BLV PVL significantly increased over time after both the primary and secondary KLH inoculations. BLV primarily infects B cells (5) 
B-cell population in BLV
+ cows at all time points could indicate a deficiency in either developing or maintaining B-cell memory, which would be especially detrimental for any immune response dependent on antibody production. Another concerning result was that the overall B-cell population, and the CD5 dim+ B-cell population in particular, in BLV + cows had lower MHCII surface expression, which could also impair humoral immunity development that is required for isotype switching. Although in this study we did not observe reduced IgG1 or IgG2 antibody production in BLV + cows, this may be because we only tested a secondary antigen exposure. A previous study has found a reduced IgG2 antibody production in BLV + cows after repeated vaccination (9 (19) , but CD5 expression on B cells may also be induced after stimulation through the B-cell receptor (20) , and it is possible that the CD5 dim+ and CD5 bright+ populations reflect these different patterns of CD5 expression. Our data suggests that the distinction is relevant in the context of BLV infection, but our study was unable elucidate the function of these distinct B-cell subtypes. While the potential effect of BLV infection on B cells is obvious, it is less clear how BLV infection affects the T-cell compartment, although T-cell irregularities have been previously observed (6) . We measured the circulating CD45R0 + T-cell populations to investigate effector/memory T cells (23) . Both the CD4 + and CD8 + CD45R0 + T-cell populations increased over time after KLH+ DDA stimulation, although the abundance of the cell types was equivalent between BLV + and BLV − cows. While the γδ + CD45R0 + T-cell population remained mostly constant after KLH+ DDA exposure, BLV + cows exhibited a large overall reduction in their γδ + CD45R0 + T-cell population. Although γδ + CD45R0 + T cells are not a well-characterized cell population, CD45R0 expression likely indicates current or prior activation, although it is unclear whether this activation would be innate or adaptive or both (24) .
We were also interested in investigating IFNγ and IL4 productions in response to KLH stimulation in vitro. While we were unable to detect increased cytokine production in KLHstimulated cell culture, we found that both CD4
+ and CD8 + T cells in cattle is not well-studied, evidence from humans and mice suggest that CD8 + T cells may also be polarized based upon their cytokine secretion and that this cytokine secretion can contribute to the overall balance of a cell-mediated versus humoral immune response (25, 26) .
While our experiment was unable to detect any differences in antigen-specific activation in T cells from BLV + cows, we did detect overall differences in circulating γδ + T cells and in αβ and γδ + T-cell cytokine production in vitro. The considerable reduction in circulating CD45R0
+ γδ + T cells in BLV + cows could suggest an impairment of effector or memory γδ + T cells in BLV + cows; considering the hypothesized importance of γδ + T cells in bovine immunity (27) , an impairment in this T-cell subtype could have serious consequences on both innate and adaptive immunities in cattle, including reduced responsiveness to vaccination and less immune protection from pathogens including Mycobacterium bovis and Leptospira borgpetersenii serovar Hardjo (28) . Our in vitro experiments suggest that αβ T cells in BLV + cattle could be more predisposed to produce IL4 as compared to αβ T cells from healthy, BLV − cattle. If BLV + cattle immunity is more skewed toward IL4 over IFNγ production, this could have profound effects upon infections that depend on Th1 versus Th2 immunity for effective pathogen clearance.
This study was conducted to investigate B-and T-cell responses in BLV + cows to a primary and secondary antigenic immune challenge. While evidence demonstrates that BLV-infected cattle have atypical immunity in comparison to BLV − cows (6), little research has investigated whether BLV + cows would exhibit abnormal immune responses to a primary challenge, or if abnormal adaptive immunity in BLV + cattle was the cumulative effect of multiple antigenic challenges. Our study did find antigen-specific deficiencies in B-cell immunity during a primary immune response, indicating that BLV infection can interfere with antigen-specific immunity without many re-exposures to antigen. While we were unable to detect antigen-specific T-cell responses in vitro, we did detect abnormalities in circulating γδ + T cells in BLV + cows, as well as a potential bias for IL4-producing αβ T cells. These data demonstrate that BLV infection can have a detectable impact on immune stimulation even upon a primary antigen exposure, which would likely mean that negative impacts of BLV infection on herd health could occur immediately upon a secondary infection.
eThics sTaTeMenT
All protocols were reviewed and approved by the Michigan State University Institutional Animal Use and Care Committee (AUF# 04/15-061-00).
aUThOr cOnTriBUTiOns MF led the study and was involved in the study conception, design, execution, analysis, and interpretation of data. MF wrote the manuscript. KS contributed to study design, execution and interpretation of data, and manuscript editing. OB contributed to the study execution and analysis of data and wrote the PVL methods section of the manuscript. JW contributed to the study execution and manuscript editing. CD contributed to the study execution and manuscript editing. PB contributed to the study conception and design and manuscript editing. PC contributed to the study conception, design, and interpretation and manuscript editing. + dim and bright populations, the upper right quadrant was used to denote CD5 + cells. A rectangle gate was used to select CD5 bright+ cells, and cells inside the quadrant gate and outside the rectangle gate were determined to be CD5 dim+ cells. Representative plots are from fresh labeling on D56 and feature samples from representative BLV − and BLV + cows.
